

ASX RELEASE

Ellex Medical Lasers Limited (ASX:ELX)

Adelaide, Australia

Date: 19 May 2015

Release: Immediate

Topic: More Scientific Research Validates Clinical Effect of 2RT



Adelaide, Australia, 19 May 2015 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical technologies for the diagnosis and treatment of eye disease, today announced additional scientific research validating the method of action of the Company’s proprietary Retinal Rejuvenation Therapy (2RT™) in the treatment of early age-related macular degeneration (AMD).

Presented at the April 2015 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Denver, USA, the research investigated the effect of 2RT™ on cultures of animal retinal pigment epithelium (RPE), the layer of cells responsible for maintaining and nourishing the retina.

The research was conducted by John P. Wood, BSc (Hons), DPhil, Glyn Chidlow, BSc (Hons), DPhil, Marzieh Tahmasebi and Malcolm Plunkett of the Hanson Institute (Adelaide, Australia), and Robert J. Casson, DPhil FRANZCO, of the Royal Adelaide Hospital (Adelaide, Australia).

The research found that directly following treatment by 2RT™ of the targeted RPE cells the surrounding, surviving cells grew into the vacated spaces and stimulated expression of a range of protein factors, triggering a regenerative effect on nearby RPE cells.

According to Ellex CEO Tom Spurling, the new research has confirmed the positive cellular response induced by 2RT™, validating its previously postulated method of action.

“Building on the work undertaken previously at the Centre for Eye Research Australia (CERA) and the University of Melbourne, the research by Dr Wood and colleagues continues to validate the growing body of clinical and scientific evidence for 2RT in the treatment of early-stage AMD.”

“We are particularly excited that this regenerative process may offer the potential for 2RT to emerge as a platform technology that could provide additional, alternative therapeutic applications, which will form part of our ongoing scientific and clinical investigations,” added Mr. Spurling.

The research is expected to be published in a peer-review publication during the 2016 financial year.

ABOUT ELLEX

Ellex Medical Lasers Limited (ASX:ELX) is a global leader in the development of medical technologies for the diagnosis and treatment of eye disease. With more than 20,000 systems delivered to market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan, France, Germany and Australia, and a network of distribution partners in more than 100 countries. In recent years, Ellex has diversified its product range beyond lasers and ultrasound equipment to include distribution of a number of complementary third-party ophthalmic products. On 31 December 2013 Ellex acquired the Canaloplasty microcatheter-based glaucoma surgical treatment from iScience Interventional, Inc.

For additional information about Ellex and its products, please visit www.ellex.com

For further information on Ellex, please contact:

Tom Spurling, CEO
Ellex Medical Lasers Limited
82 Gilbert Street, Adelaide, SA, 5000
W +61 8 8104 5293 | M +61 417 818 658
tspurling@ellex.com

Victor Previn, Chairman
Ellex Medical Lasers Limited
82 Gilbert Street, Adelaide, SA, 5000
W +61 8 8104 5200 | M +61 414 661 994
vprevin@ellex.com

Maria Maieli, Company Secretary
Ellex Medical Lasers Limited
82 Gilbert Street, Adelaide, SA, 5000
W +61 8 8104 5200
mmaieli@ellex.com